Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mazal Plant Pharmaceuticals has filed a provisional patent for its cholesterol/HDL investigational new drug formulation. The company has already been issued a patent covering its original, first generation formula.
Subscribe to our email newsletter
Mazal Plant Pharmaceuticals has also received approval to conduct a large-scale, double-blind, four-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, statin + placebo or MAHDL + statin for four months and tested for changes in HDL, LDL, cholesterol, triglycerides and CRP serum levels.
Eliyahu Tolchinsky, Mazal’s CEO, said: “Building the company’s intellectual portfolio is an important part of building Mazal Plant Pharmaceuticals in tandem with pending clinical trials.”